354 related articles for article (PubMed ID: 29101303)
21. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma.
Kuhlmann L; Nadler WM; Kerner A; Hanke SA; Noll EM; Eisen C; Espinet E; Vogel V; Trumpp A; Sprick MR; Roesli CP
Pancreas; 2017 Mar; 46(3):311-322. PubMed ID: 27846146
[TBL] [Abstract][Full Text] [Related]
22. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Duan K; Jang GH; Grant RC; Wilson JM; Notta F; O'Kane GM; Knox JJ; Gallinger S; Fischer S
Sci Rep; 2021 Jul; 11(1):14951. PubMed ID: 34294813
[TBL] [Abstract][Full Text] [Related]
23. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.
Cai L; Michelakos T; Ferrone CR; Zhang L; Deshpande V; Shen Q; DeLeo A; Yamada T; Zhang G; Ferrone S; Wang X
Oncotarget; 2017 Jun; 8(23):37646-37656. PubMed ID: 28430580
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
25. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
26. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
Golan T; Javle M
J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866
[TBL] [Abstract][Full Text] [Related]
27. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
29. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
30. Cell of Origin Influences Pancreatic Cancer Subtype.
Flowers BM; Xu H; Mulligan AS; Hanson KJ; Seoane JA; Vogel H; Curtis C; Wood LD; Attardi LD
Cancer Discov; 2021 Mar; 11(3):660-677. PubMed ID: 34009137
[TBL] [Abstract][Full Text] [Related]
31. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
Xia R; Hu C; Ye Y; Zhang X; Li T; He R; Zheng S; Wen X; Chen R
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36825600
[TBL] [Abstract][Full Text] [Related]
32. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
33. CLIC1 overexpression is associated with poor prognosis in pancreatic ductal adenocarcinomas.
Jia N; Dong S; Zhao G; Gao H; Li X; Zhang H
J Cancer Res Ther; 2016; 12(2):892-6. PubMed ID: 27461670
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
35. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma.
Yang JY; Jiang SH; Liu DJ; Yang XM; Huo YM; Li J; Hua R; Zhang ZG; Sun YW
Sci Rep; 2015 May; 5():10575. PubMed ID: 26015068
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
37. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients.
Sun Y; Wu G; Cheng KS; Chen A; Neoh KH; Chen S; Tang Z; Lee PF; Dai M; Han RPS
EBioMedicine; 2019 Aug; 46():133-149. PubMed ID: 31375425
[TBL] [Abstract][Full Text] [Related]
38. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
Cinar P; Ko AH
J Natl Compr Canc Netw; 2014 Feb; 12(2):167-72. PubMed ID: 24586078
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
40. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
